Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

BT474 tumors in the presence or absence of SHP2

ABSTRACT: The first bona fide PTP proto-oncogene was the Src-homology 2 domain-containing phosphatase SHP2 (encoded by PTPN11), an ubiquitously expressed PTP that transduces mitogenic, pro-survival, cell fate and/or pro-migratory signals from numerous growth factor-, cytokine- and extracellular matrix receptors. In malignancies, SHP2 is hyperactivated either downstream of oncoproteins or by mutations.We provide analysis of the breast cancer cells BT474 grown as xenografts in the presence or absence of SHP2 for 30 days. The HER2-postive breast cancer cell line BT474 was transduced with a doxycycline-inducible lentiviral vector expressing a CTRL miR or SHP2 miR1 or SHP2 miR2. Cells from each group were injected in imuunodeficinet mice and after tumor development, the knockdown of SHP2 was induced for 30 days in vivo. At day 30, tumors were dissected and RNA isolated for gene expression analysis.

ORGANISM(S): Homo sapiens

SUBMITTER: Tim Roloff 

PROVIDER: E-GEOD-34523 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

Json Xml
altmetric image

Publications

Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop.

Aceto Nicola N   Sausgruber Nina N   Brinkhaus Heike H   Gaidatzis Dimos D   Martiny-Baron Georg G   Mazzarol Giovanni G   Confalonieri Stefano S   Quarto Micaela M   Hu Guang G   Hu Guang G   Balwierz Piotr J PJ   Pachkov Mikhail M   Elledge Stephen J SJ   van Nimwegen Erik E   Stadler Michael B MB   Bentires-Alj Mohamed M  

Nature medicine 20120304 4

New cancer therapies are likely to arise from an in-depth understanding of the signaling networks influencing tumor initiation, progression and metastasis. We show a fundamental role for Src-homology 2 domain-containing phosphatase 2 (SHP2) in these processes in human epidermal growth factor receptor 2 (HER2)-positive and triple-negative breast cancers. Knockdown of SHP2 eradicated breast tumor-initiating cells in xenograft models, and SHP2 depletion also prevented invasion in three-dimensional  ...[more]

Similar Datasets

Transcriptomics Primary TNBC tumor in the presence or absence of SHP2
2012-01-16 | E-GEOD-35118 | biostudies-arrayexpress
Transcriptomics BT474 tumors in the presence or absence of SHP2
2011-12-20 | GSE34523 | GEO
Transcriptomics MCF10A-HER2/3 cells grown in 3D cultures in the presence or absence of SHP2
2011-12-20 | E-GEOD-34524 | biostudies-arrayexpress
Transcriptomics BT474 tumors and MCF10A-HER2/3 cells in the presence or absence of SHP2
2011-12-20 | E-GEOD-34525 | biostudies-arrayexpress
Transcriptomics Primary TNBC tumor in the presence or absence of SHP2
2012-01-16 | GSE35118 | GEO
Transcriptomics MCF10A-HER2/3 cells grown in 3D cultures in the presence or absence of SHP2
2011-12-20 | GSE34524 | GEO
Transcriptomics SUM159 cells grown in 2D cultures in the presence or absence of SHP2
2022-06-23 | GSE182033 | GEO
Transcriptomics Shp2 transcriptome in melanoma
2016-07-03 | E-GEOD-53282 | biostudies-arrayexpress
Transcriptomics SHP2 Is Required for BCR-ABL1-Induced Hematologic Neoplasms
2017-06-06 | GSE99656 | GEO
Transcriptomics Pancreatic tissue of 9 week old mice with genotypes Ptf1a-Cre;LSL-KrasG12D and Ptf1a-Cre;LSL-KrasG12D;Ptpn11fl/fl
2018-03-30 | E-MTAB-6399 | biostudies-arrayexpress